We urge you to utilize D Pharm LTD fundamental analysis to see if markets are at this moment mispricing the company. In plain English you can exercise it to find out if D Pharm LTD is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. . We found twenty-nine available fundamental indicators for D Pharm LTD which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all D Pharm LTD fundamentals including its Revenue, EBITDA, Cash and Equivalents, as well as the relationship between Gross Profit and Net Income . Use D Pharm to enhance returns of your portfolios. The stock experiences normal upward fluctuation. Check odds of D Pharm to be traded at S451.5 in 30 days.
D Pharm Company Summary
D Pharm competes with Kamada Ltd, Compugen Ltd, BioTime, Clal Biotechnology, and Pluristem Therapeutics. D-Pharm LTD., a drug-development company, focuses on the development of drugs for the treatment of central nervous system conditions. D-Pharm LTD. was founded in 1993 and is based in Rehovot, Israel. D Pharm operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.
D Pharm LTD is rated below average in cash and equivalents category among related companies. It is rated below average in price to sales category among related companies . The ratio of Cash and Equivalents to Price to Sales for D Pharm LTD is about 8,486
D Pharm Market Fundamentals
D Pharm Financial Distress Probability
Chance of Financial Distress
D Pharm LTD has less than 1 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info